TLPH · Talphera, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-03 |
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be |
| 2026-08-12 |
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. |
| 2026-08-05 |
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and |
| 2026-05-13 |
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. |
| 2026-05-07 |
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 |
| 2026-03-25 |
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for |
| 2026-03-23 |
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026 Cash and investments of $20.4 |
| 2026-03-18 |
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor |
| 2026-03-02 |
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao Teixeira SAN MATEO, Calif., March 2, 2026 |
| 2025-11-12 |
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million ; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late |
| 2025-11-05 |
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 |
| 2025-10-21 |
Talphera Announces the Appointment of Joe Todisco to Board of Directors
SAN MATEO, Calif. , Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco , the CEO |
| 2025-09-08 |
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one |
Past events
Source: https://ir.talphera.com/